Brokerage firms expect West Pharmaceutical Services, Inc. (NYSE: WST) to post sales of $ 709.10 million for the current fiscal quarter, according to Zack. Three analysts have released earnings estimates for West Pharmaceutical Services. The highest sales estimate is $ 710.50 million and the lowest is $ 708.00 million. West Pharmaceutical Services reported sales of $ 580.20 million in the same quarter last year, suggesting a positive year-over-year growth rate of 22.2%. The company is expected to release its next quarterly earnings report on Thursday, February 17.
On average, analysts expect West Pharmaceutical Services to report annual revenue of $ 2.81 billion for the current year. For the next fiscal year, analysts predict the company will post sales of $ 3.12 billion, with estimates ranging from $ 3.04 billion to $ 3.23 billion. Zacks Investment Research’s sales calculations are an average based on a survey of sales-side research companies that cover West Pharmaceutical Services.
West Pharmaceutical Services (NYSE: WST) last reported its results on Thursday, October 28. The medical device supplier reported EPS of $ 2.06 for the quarter, beating analyst consensus estimates of $ 1.80 by $ 0.26. The company posted revenue of $ 706.50 million for the quarter, compared to analysts’ expectations of $ 687.09 million. West Pharmaceutical Services had a net margin of 22.85% and a return on equity of 30.35%. The company’s quarterly revenue increased 28.9% year-on-year. During the same period of the previous year, the company posted EPS of $ 1.15.
Separately, Zacks investment research downgraded West Pharmaceutical Services shares from a “buy” rating to a “hold” rating and set a price target of $ 438.00 for the stock. in a research report on Friday, November 12.
NYSE: WST opened at $ 390.47 on Friday. The company’s fifty-day average mobile price is $ 436.44, and its 200-day average mobile price is $ 422.56. West Pharmaceutical Services has a one-year minimum of $ 253.85 and a one-year maximum of $ 475.35. The company has a debt to equity ratio of 0.10, a current ratio of 2.86 and a rapid ratio of 2.23. The company has a market cap of $ 28.93 billion, a price / earnings ratio of 48.45, a price / earnings-growth ratio of 2.00, and a beta of 0.97.
The company also recently announced a quarterly dividend, which will be paid on Wednesday, February 2. Investors of record on Wednesday, January 19 will receive a dividend of $ 0.18. This represents an annualized dividend of $ 0.72 and a return of 0.18%. The ex-dividend date is Tuesday, January 18. West Pharmaceutical Services’ payout ratio is 8.93%.
Large investors have recently changed their holdings in the company. FMR LLC increased its stake in West Pharmaceutical Services by 38.9% in the 2nd quarter. FMR LLC now owns 1,262,638 shares of the medical device supplier valued at $ 453,413,000 after acquiring an additional 353,917 shares during the period. Price T Rowe Associates Inc. MD increased its stake in shares of West Pharmaceutical Services by 6.5% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 5,338,372 shares of the medical device supplier valued at $ 1,917,009,000 after purchasing an additional 325,327 shares during the last quarter. Amundi acquired a new position in shares of West Pharmaceutical Services during the 2nd quarter for a value of approximately $ 108,087,000. Morgan Stanley increased its stake in shares of West Pharmaceutical Services by 79.5% during the 2nd quarter. Morgan Stanley now owns 565,478 shares of the medical device supplier valued at $ 203,064,000 after purchasing an additional 250,453 shares in the last quarter. Finally, APG Asset Management NV increased its stake in the shares of West Pharmaceutical Services by 8.2% during the second quarter. APG Asset Management NV now owns 2,531,368 shares of the medical device supplier valued at $ 766,518,000 after purchasing an additional 190,900 shares during the last quarter. Institutional investors and hedge funds hold 92.65% of the company’s shares.
West Pharmaceutical Services Company Profile
West Pharmaceutical Services, Inc manufactures and markets pharmaceuticals, biologics, vaccines, and consumer health products. It operates through the following business sectors: Exclusive Products and Contract Manufactured Products. The Proprietary Products segment offers proprietary drug packaging, containment and delivery products, as well as analytical laboratory services, to biologic, generic and pharmaceutical customers.
Further reading: trade deficit
For more information on Zacks Investment Research’s research offerings, visit Zacks.com
This instant news alert was powered by storytelling technology and financial data from MarketBeat to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team before publication. Please send any questions or comments about this story to [email protected]
Should you invest $ 1,000 in West Pharmaceutical Services now?
Before you consider West Pharmaceutical Services, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat identified the five stocks that top analysts quietly whisper to their clients to buy now before the larger market takes hold of… and West Pharmaceutical Services was not on the list.
While West Pharmaceutical Services currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better bets.
See the 5 actions here